NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Price, News & Analysis

$2.22
-0.04 (-1.77%)
(As of 04/24/2024 ET)
Today's Range
$2.22
$2.29
50-Day Range
$1.38
$2.88
52-Week Range
$1.08
$3.79
Volume
91,807 shs
Average Volume
375,438 shs
Market Capitalization
$145.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25

Regulus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
226.6% Upside
$7.25 Price Target
Short Interest
Bearish
9.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.52) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.36 out of 5 stars

Medical Sector

473rd out of 907 stocks

Pharmaceutical Preparations Industry

216th out of 419 stocks

RGLS stock logo

About Regulus Therapeutics Stock (NASDAQ:RGLS)

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

RGLS Stock Price History

RGLS Stock News Headlines

The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
RGLS Mar 2024 7.500 put
Regulus Therapeutics Inc
Regulus Therapeutics files for $150M mixed shelf
Regulus Therapeutics Inc RGLS
See More Headlines
Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/25/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGLS
CUSIP
75915K10
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.25
High Stock Price Target
$11.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+226.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-30,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.05 per share

Miscellaneous

Free Float
59,959,000
Market Cap
$145.32 million
Optionable
Optionable
Beta
1.57
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives


RGLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Regulus Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGLS shares.
View RGLS analyst ratings
or view top-rated stocks.

What is Regulus Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 12 month price targets for Regulus Therapeutics' shares. Their RGLS share price targets range from $3.00 to $11.00. On average, they expect the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 226.6% from the stock's current price.
View analysts price targets for RGLS
or view top-rated stocks among Wall Street analysts.

How have RGLS shares performed in 2024?

Regulus Therapeutics' stock was trading at $1.28 on January 1st, 2024. Since then, RGLS stock has increased by 73.4% and is now trading at $2.22.
View the best growth stocks for 2024 here
.

When is Regulus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RGLS earnings forecast
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, meeting analysts' consensus estimates of ($0.40).

When did Regulus Therapeutics' stock split?

Regulus Therapeutics shares reverse split on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (7.64%). Insiders that own company stock include Christopher Ray Aker, Crispina Calsada, Denis Drygin and Joseph P Hagan.
View institutional ownership trends
.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RGLS) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners